Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial

Erin C. O'Neil, Jiayan Huang, Eric Suhler, James P. Dunn, Victor L. Perez, David C. Gritz, Kathy McWilliams, Ellen Peskin, Gui Shuang Ying, Vatinee Y. Bunya, Maureen G. Maguire, John H. Kempen

Research output: Contribution to journalArticle

Abstract

Currently available treatment options for non-infectious scleritis, including non-steroidal anti-inflammatory drugs, systemic corticosteroids and immunosuppressive therapies, have both efficacy and side effect limitations. Iontophoretic delivery of corticosteroids has been demonstrated to be effective for anterior uveitis and represents a potential new approach to scleritis therapy. We hypothesised that iontophoretic delivery would provide effective and precise medication delivery to the sclera, while limiting systemic exposure and side effects. This first-in-human randomised, double-masked, dose-escalating study of iontophoretic administration of dexamethasone phosphate for scleritis suggests the treatment to be well tolerated and safe (within the limitations of the 18 patients sample size). There was a suggestion of efficacy in the lowest (1.2 mA/min at 0.4 mA) dose group (corresponding to the superficial location of scleritis compared with anterior uveitis), with 5/7 eyes meeting the primary efficacy outcome within 28 days. Our results suggest iontophoretic delivery of corticosteroids is a promising potential treatment for scleritis, with favourable safety and preliminary efficacy results in this phase 1 trial. Trial registration number NCT01059955.

Original languageEnglish (US)
Pages (from-to)1011-1013
Number of pages3
JournalBritish Journal of Ophthalmology
Volume102
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

dexamethasone 21-phosphate
Scleritis
Clinical Trials
Anterior Uveitis
Adrenal Cortex Hormones
Therapeutics
Sclera
Immunosuppressive Agents
Sample Size
Anti-Inflammatory Agents
Safety

Keywords

  • Clinical Trial
  • Dr.ugs
  • Sclera and Episclera
  • Treatment other

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial. / O'Neil, Erin C.; Huang, Jiayan; Suhler, Eric; Dunn, James P.; Perez, Victor L.; Gritz, David C.; McWilliams, Kathy; Peskin, Ellen; Ying, Gui Shuang; Bunya, Vatinee Y.; Maguire, Maureen G.; Kempen, John H.

In: British Journal of Ophthalmology, Vol. 102, No. 8, 01.08.2018, p. 1011-1013.

Research output: Contribution to journalArticle

O'Neil, EC, Huang, J, Suhler, E, Dunn, JP, Perez, VL, Gritz, DC, McWilliams, K, Peskin, E, Ying, GS, Bunya, VY, Maguire, MG & Kempen, JH 2018, 'Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial', British Journal of Ophthalmology, vol. 102, no. 8, pp. 1011-1013. https://doi.org/10.1136/bjophthalmol-2017-311610
O'Neil, Erin C. ; Huang, Jiayan ; Suhler, Eric ; Dunn, James P. ; Perez, Victor L. ; Gritz, David C. ; McWilliams, Kathy ; Peskin, Ellen ; Ying, Gui Shuang ; Bunya, Vatinee Y. ; Maguire, Maureen G. ; Kempen, John H. / Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial. In: British Journal of Ophthalmology. 2018 ; Vol. 102, No. 8. pp. 1011-1013.
@article{834b0ea38a2042648f9ae3bb3548dcc1,
title = "Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial",
abstract = "Currently available treatment options for non-infectious scleritis, including non-steroidal anti-inflammatory drugs, systemic corticosteroids and immunosuppressive therapies, have both efficacy and side effect limitations. Iontophoretic delivery of corticosteroids has been demonstrated to be effective for anterior uveitis and represents a potential new approach to scleritis therapy. We hypothesised that iontophoretic delivery would provide effective and precise medication delivery to the sclera, while limiting systemic exposure and side effects. This first-in-human randomised, double-masked, dose-escalating study of iontophoretic administration of dexamethasone phosphate for scleritis suggests the treatment to be well tolerated and safe (within the limitations of the 18 patients sample size). There was a suggestion of efficacy in the lowest (1.2 mA/min at 0.4 mA) dose group (corresponding to the superficial location of scleritis compared with anterior uveitis), with 5/7 eyes meeting the primary efficacy outcome within 28 days. Our results suggest iontophoretic delivery of corticosteroids is a promising potential treatment for scleritis, with favourable safety and preliminary efficacy results in this phase 1 trial. Trial registration number NCT01059955.",
keywords = "Clinical Trial, Dr.ugs, Sclera and Episclera, Treatment other",
author = "O'Neil, {Erin C.} and Jiayan Huang and Eric Suhler and Dunn, {James P.} and Perez, {Victor L.} and Gritz, {David C.} and Kathy McWilliams and Ellen Peskin and Ying, {Gui Shuang} and Bunya, {Vatinee Y.} and Maguire, {Maureen G.} and Kempen, {John H.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1136/bjophthalmol-2017-311610",
language = "English (US)",
volume = "102",
pages = "1011--1013",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial

AU - O'Neil, Erin C.

AU - Huang, Jiayan

AU - Suhler, Eric

AU - Dunn, James P.

AU - Perez, Victor L.

AU - Gritz, David C.

AU - McWilliams, Kathy

AU - Peskin, Ellen

AU - Ying, Gui Shuang

AU - Bunya, Vatinee Y.

AU - Maguire, Maureen G.

AU - Kempen, John H.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Currently available treatment options for non-infectious scleritis, including non-steroidal anti-inflammatory drugs, systemic corticosteroids and immunosuppressive therapies, have both efficacy and side effect limitations. Iontophoretic delivery of corticosteroids has been demonstrated to be effective for anterior uveitis and represents a potential new approach to scleritis therapy. We hypothesised that iontophoretic delivery would provide effective and precise medication delivery to the sclera, while limiting systemic exposure and side effects. This first-in-human randomised, double-masked, dose-escalating study of iontophoretic administration of dexamethasone phosphate for scleritis suggests the treatment to be well tolerated and safe (within the limitations of the 18 patients sample size). There was a suggestion of efficacy in the lowest (1.2 mA/min at 0.4 mA) dose group (corresponding to the superficial location of scleritis compared with anterior uveitis), with 5/7 eyes meeting the primary efficacy outcome within 28 days. Our results suggest iontophoretic delivery of corticosteroids is a promising potential treatment for scleritis, with favourable safety and preliminary efficacy results in this phase 1 trial. Trial registration number NCT01059955.

AB - Currently available treatment options for non-infectious scleritis, including non-steroidal anti-inflammatory drugs, systemic corticosteroids and immunosuppressive therapies, have both efficacy and side effect limitations. Iontophoretic delivery of corticosteroids has been demonstrated to be effective for anterior uveitis and represents a potential new approach to scleritis therapy. We hypothesised that iontophoretic delivery would provide effective and precise medication delivery to the sclera, while limiting systemic exposure and side effects. This first-in-human randomised, double-masked, dose-escalating study of iontophoretic administration of dexamethasone phosphate for scleritis suggests the treatment to be well tolerated and safe (within the limitations of the 18 patients sample size). There was a suggestion of efficacy in the lowest (1.2 mA/min at 0.4 mA) dose group (corresponding to the superficial location of scleritis compared with anterior uveitis), with 5/7 eyes meeting the primary efficacy outcome within 28 days. Our results suggest iontophoretic delivery of corticosteroids is a promising potential treatment for scleritis, with favourable safety and preliminary efficacy results in this phase 1 trial. Trial registration number NCT01059955.

KW - Clinical Trial

KW - Dr.ugs

KW - Sclera and Episclera

KW - Treatment other

UR - http://www.scopus.com/inward/record.url?scp=85051050539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051050539&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2017-311610

DO - 10.1136/bjophthalmol-2017-311610

M3 - Article

VL - 102

SP - 1011

EP - 1013

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 8

ER -